Alpha Sense BI

APRIL 29, 2024

Traditional due diligence for start-up investors has historically been riddled with inefficiencies—tying up resources to sort through countless documents and copious amounts of data, and manually crafting market comparisons and performance. There is no doubt that generative AI has emerged as a powerful tool in the investment space.

Capital 52

Capital Due Diligence Biotech Startups 52

Alpha Sense BI

MARCH 13, 2024

According to PwC’s Annual Global CEO survey, 54% of healthcare industry CEOs intend to make at least one acquisition in the next three years. According to an outlook published by PwC , “large-cap pharma companies are expected to continue pursuing mid-sized biotech companies to fill pipeline gaps in the face of impending patent cliffs.

Pharmaceutical 59

Pharmaceutical Hospitals Due Diligence Biotech 59

Alpha Sense BI

APRIL 19, 2024

2020 and 2021 were marked by increased innovation, accelerated growth, and workforce expansion. On the other hand, 2022 and 2023 brought mass layoffs , falling market capitalizations, and a weakening of global tech spending. In fact, projections for the global spatial computing market are valued at $269.8 billion by 2032.

Technology 69

Technology Technology Retail Biotech 69

Alpha Sense BI

MAY 5, 2023

After three volatile years, rife with challenging macroeconomic conditions — from a global pandemic and wars to far-reaching supply chain issues — the M&A space has its fair share of ups and downs. Many pharma companies with expiring patents are on the hunt to acquire biotech companies to address gaps in drug pipelines.

Biotech 97

Biotech Capital Banking Startups 97

Engage3

MAY 19, 2022

Ken served on the Board of Directors of Revionics between 2007-2011 and as Chief Scientist & VP of Innovations at SAP AG between 2006-2007. Tim Ouimet Founder & Board Observer Tim Ouimet is a Founder and Board Member at Engage3 and is a recognized industry innovator in retail pricing strategies.

Retail 52

Retail Capital Finance Biotech 52